Sarepta Therapeutics Expands Gene Therapy Center of Excellence in Columbus, Ohio
Pending state approvals, Sarepta plans to open its new center in an 85,000-square-foot facility at 3435 Stelzer Road in Columbus. All employees currently operating out of the Company’s Dublin, Ohio, office will transition to the new facility over time. Armed with the most advanced science in genetic medicine, the new center will allow Sarepta to lead the way in making Columbus an epicenter of gene therapy research and development. In addition to the new building, the company’s investment will be used toward R&D equipment.
“Sarepta is emerging as the world leader in gene therapy to treat and transform lives otherwise diminished and stolen by rare genetic disease. We are confident that gene therapy will revolutionize genetic medicine, and we chose Ohio for our Gene Therapy Center of Excellence because we believe Columbus will become a hub for genetic medicine innovation,” said Sarepta President & CEO Doug Ingram. “Our new center will strengthen the position of Columbus as a gene therapy leader, building on the advances of our long-standing partner, Nationwide Children’s Hospital.”
“We are proud to be the home of Sarepta’s new Gene Therapy Center of Excellence and to support their continued innovation within a critical field in medicine,” said Columbus Mayor Andrew J. Ginther. “The company’s investment in Columbus is a testament to why our city and region are positioned to become the most important place in the world for gene therapy development.”
From medical breakthroughs to cutting-edge technology, the Columbus Region is home to one of the top healthcare industries in the country. With several renowned healthcare systems and companies, including OhioHealth, Nationwide Children’s Hospital and Cardinal Health, the Columbus Region employs more than 45,000 in the industry. The Region’s large pool of IT talent, combined with its well-established healthcare sector, makes it a hotbed for innovation.
“Sarepta is one of the nation’s fastest growing biotechnology companies focused on the development of precision genetic medicines,” said JobsOhio President and CEO J.P. Nauseef. “With Ohio talent, Sarepta will advance its R&D of neuromuscular and central nervous system diseases at its new gene therapy R&D Center in the Columbus Region.”
Founded in 1980, Sarepta develops genetic medicines to treat rare diseases, and currently has two approved products for Duchenne muscular dystrophy (DMD) and a pipeline of more than 40 treatments in development. The company’s programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing.
Headquartered in Cambridge, Massachusetts, Sarepta has locations across four continents, and its current Central Ohio research facility in Dublin employs approximately 40 full-time workers.
“Made in America” Executive Order to Affect International Companies and FDI
Trends in Office and Industrial Parks
34th Annual Corporate Survey & the 16th Annual Consultants Survey
Another Look at Rural Economies
2019 Leading Metro Locations: Pacific and South-Atlantic Metros Dominate the List
Supply Chain Execs Respond as Pandemic Creates E-Commerce Surge